Common questions about Infectoscab 5% (FAQ)
Q: Can other topical medications, like a steroid cream, be used at the same time as Infectoscab 5%?
Official product information notes that topical corticosteroid treatment, often used for related skin reactions, must be withheld prior to applying Infectoscab 5% cream. This is to avoid potentially masking (hiding) the symptoms of the scabies infestation. Information regarding when to resume use of other topical creams is a topic for discussion with a prescribing physician.
Q: What does available research suggest about the amount of the active ingredient absorbed through the skin?
Official studies indicate that the active ingredient, permethrin, is only minimally absorbed into the body when applied to the skin. Generally, less than 2% of the dose is absorbed systemically (into the bloodstream). This minimal absorption is a key factor in the drug's profile for topical use.
Q: Why is it common for the severe itching to continue for several weeks after the treatment is completed?
Itching (pruritus) is often one of the last symptoms to resolve and may continue for up to four weeks following successful treatment. Official guidelines suggest this persistent itching is typically a temporary hypersensitivity response to the dead mites, rather than a sign that the treatment was unsuccessful. This is considered a common pattern documented in clinical use.
Q: Is it still possible to use Infectoscab 5% if a person has a known allergy to chrysanthemums?
Regulatory documents state that the cream is contraindicated (may not be used) in individuals who have a known hypersensitivity or allergy to the active substance, permethrin, or other substances called pyrethrins and pyrethroids. Since pyrethrins are chemically related to extracts from chrysanthemum plants, this caution is included in the official labeling for the product.
Q: Is it described as essential to apply the cream under the fingernails and toenails?
Application instructions from regulatory bodies advise that the cream should be applied to all areas of the body from the neck down to the soles of the feet. This specifically includes applying the cream under the fingernails and toenails to ensure complete coverage, as mites can shelter in these hard-to-reach areas.
Q: Does Infectoscab 5% kill both the adult scabies mites and their eggs as well?
Official pharmacological information indicates that the active ingredient, permethrin, is an effective ectoparasiticide. Its mechanism of action is designed to be toxic to the parasites, resulting in the destruction of the adult mites, as well as their eggs.
Q: Does Infectoscab 5% also treat other issues like head lice or pubic lice?
Infectoscab 5% cream is officially indicated only for the treatment of scabies infestations. While the active ingredient, permethrin, is used to treat lice, it is typically used in a different concentration (such as 1% lotion) for those specific conditions.
Q: What is the difference between post-scabies itch and a sign of re-infestation after using the cream?
The post-scabies itch is a common residual symptom that can last up to four weeks after successful treatment. Re-infestation or treatment failure is typically suspected only if the patient develops new lesions or if live mites are confirmed by clinical examination 14 days or more after the first application.
Q: Is a persistent or worsening rash a definite sign that Infectoscab 5% did not work?
Official information indicates that a persistent or worsening rash is typically not interpreted as an immediate sign of treatment failure. Regulatory documents note that the skin reaction and inflammation associated with the infestation may be temporarily exacerbated (made worse) by the treatment itself. This is often part of the natural healing process.
Q: How is the success of Infectoscab 5% treatment typically measured by healthcare professionals?
Treatment success is evaluated clinically, usually in a follow-up appointment two to four weeks after treatment. Success is determined by a physician based on the absence of new burrow marks or lesions and the demonstration of no live mites during a physical check.
Q: Is there evidence of scabies mites developing resistance to the active ingredient in Infectoscab 5%?
Scientific literature and research overviews note localized instances of reduced mite sensitivity to the cream in certain geographical areas. This reduced sensitivity may be a factor in some treatment outcomes, and official sources recommend careful consideration of this pattern when evaluating efficacy.
Q: What are the excipients (non-active ingredients) in Infectoscab 5% and why are they listed?
Excipients are the non-active ingredients, such as the cream base or preservatives. These are listed in official documents because some, like parahydroxybenzoates or butylhydroxytoluene, may cause local skin reactions or mild irritation in sensitive individuals. The list ensures patients are aware of all components.
Q: What should a person do if Infectoscab 5% cream is accidentally swallowed?
Infectoscab 5% is for cutaneous use only and must not be swallowed. In the event of accidental ingestion, official guidance directs contact with a physician or Poison Control Centre for assessment.
Q: How should clothing, towels, and bedding be cleaned after treatment with Infectoscab 5%?
Public health guidelines advise decontaminating any items that came into contact with the patient in the days prior to treatment. This typically involves washing in hot water and drying in a hot dryer, dry-cleaning, or sealing items in a plastic bag for at least 72 hours.
Q: Is it standard practice for all close contacts or family members to receive treatment with the cream?
Yes, regulatory and public health guidelines advise that all close contacts and family members who have had prolonged skin-to-skin contact with the infested person should be treated at the same time. This is recommended even if the contacts do not currently show any symptoms.
Q: When is a person considered no longer contagious and able to return to work or school?
According to public health guidelines, a person is generally considered no longer contagious 24 hours after the completion of the first treatment. As the mites are quickly killed, return to work or school can often resume the following day.
Q: Can Infectoscab 5% make existing eczema or dermatitis temporarily worse?
Official precautions note that the cream may cause a temporary exacerbation of pre-existing skin conditions that involve inflammation, pruritus, or rash. Patients with such conditions should be aware of this possibility, though it does not generally preclude use.
Q: Why is a single application of Infectoscab 5% usually considered sufficient in many cases?
Official labeling states that one application is generally curative when applied thoroughly and left on for the full required duration. The medication is highly effective at killing the mites and eggs within the application window, making a second treatment unnecessary for most individuals.
Q: Is there specific clinical data or research on the use of Infectoscab 5% in pregnant women?
The active ingredient, permethrin, is classified as Pregnancy Category B by the FDA. This indicates that while animal studies have shown no harm to the fetus, there are no adequate and well-controlled clinical studies in pregnant women. Use during pregnancy is permitted only when considered clearly needed.
Q: Why do official guidelines often mention a risk of fire hazard related to treated fabrics?
This caution is related to the cream base, which contains excipients (such as paraffin) that are flammable. Users are explicitly warned that if the product comes into contact with clothing, bedding, or dressings, the fabric can be easily ignited by a naked flame, and users should keep away from fire sources.
Q: Are there specific medical conditions that generally make a person ineligible to use Infectoscab 5%?
The medicine is contraindicated (may not be used) primarily for individuals with known hypersensitivity to the ingredients or related substances. Absolute prohibition also extends to infants less than 2 months of age due to limited data on safety and effectiveness in that group.
